摘要
目的比较碳酸锂联合利培酮与联合奎硫平治疗躁狂发作的临床疗效和安全性。方法将68例急性躁狂发作患者随机分为两组，研究组32例，对照组36例，两组均口服碳酸锂治疗，研究组联合利培酮治疗，对照组联合奎硫平治疗，观察8周。于治疗前及治疗1周、2周、4周、8周末采用躁狂量表和副反应量表评定临床疗效及不良反应。结果治疗后两组躁狂量表总分均呈持续性下降，研究组治疗1周、2周末均显著高于对照组（P〈0．05），4周、8周末与对照组则无显著性差异（P〉0．05）；治疗8周末研究组有效率为93．8％，对照组为88．9％，两组无显著性差异（X2=0．50，P〉0．05）；研究组联用氯硝西泮比率较高，但锥外系反应、心血管症状、神经毒性反应发生率均较低。结论碳酸锂联合利培酮与联合奎硫平治疗躁狂发作总体疗效相当，但碳酸锂联合奎硫平治疗起效更快，可作为治疗急性躁狂发作的首选联合用药。
Objective To compare the clinical efficacy and safety of lithium carbonate plus risperidone or quetiapine in acute manic episode. Methods Sixty-eight acute manic episode patients were randomized to research（n=32） and control group（n=36）, both groups took orally lithium carbonate, the research group was plus risperidone and the control plus quetiapine for 8 weeks. Clinical efficacies were assessed with the Bech-Rafaelsen Mania Scale（BRMS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 1st, 2nd, 4th and 8th week. Results After treatment, BRMS scores of both groups lowered continously, those were significantly higher at the end of the 1st and 2nd week （P〈0.05） in the research than in the control group and had no significant differences at the end of the 4th and 8th week（P〉0.05） ; at the end of the 8th week, effective rates were respectively 93.8% in the research and 88. 9% in the control group, which showed no significant difference（x^2 =0.50,P〉0. 05）;the rate of the research plus clonazepam was higher, but incidences of extrapyramidal reactions, cadiovascular syrup- toms and neurotoxicity were lower. Conclusion Both group have an equivalent general efficacy in the treatment of acute manic episode; but lithium carbonate plus risperidone takes effect more rapidly and can be used as the first choice in the treatment of acute manic episode.
出处
《临床心身疾病杂志》
CAS
2010年第4期326-327,346,共3页
Journal of Clinical Psychosomatic Diseases
